% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Shu:289472,
author = {J. Shu and W. Xie and Z. Chen and R. Offringa$^*$ and Y. Hu
and H. Mei},
title = {{T}he enchanting canvas of {CAR} technology: {U}nveiling
its wonders in non-neoplastic diseases.},
journal = {Med},
volume = {5},
number = {6},
issn = {2666-6340},
address = {Amsterdam},
publisher = {Elsevier},
reportid = {DKFZ-2024-00794},
pages = {495-529},
year = {2024},
note = {2024 Jun 14;5(6):495-529},
abstract = {Chimeric antigen receptor (CAR) T cells have made a
groundbreaking advancement in personalized immunotherapy and
achieved widespread success in hematological malignancies.
As CAR technology continues to evolve, numerous studies have
unveiled its potential far beyond the realm of oncology.
This review focuses on the current applications of CAR-based
cellular platforms in non-neoplastic indications, such as
autoimmune, infectious, fibrotic, and cellular
senescence-associated diseases. Furthermore, we delve into
the utilization of CARs in non-T cell populations such as
natural killer (NK) cells and macrophages, highlighting
their therapeutic potential in non-neoplastic conditions and
offering the potential for targeted, personalized therapies
to improve patient outcomes and enhanced quality of life.},
subtyp = {Review Article},
keywords = {CAR (Other) / CAR macrophage (Other) / CAR-NK (Other) /
autoimmune diseases (Other) / cellular senescence (Other) /
fibrotic diseases (Other) / infectious diseases (Other)},
cin = {D200},
ddc = {610},
cid = {I:(DE-He78)D200-20160331},
pnm = {314 - Immunologie und Krebs (POF4-314)},
pid = {G:(DE-HGF)POF4-314},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:38608709},
doi = {10.1016/j.medj.2024.03.016},
url = {https://inrepo02.dkfz.de/record/289472},
}